Table 1. Participant demographic overview including statistical analysis of population differences.
| Healthy Controls | Narcolepsy Cataplexy | Parkinson’s Disease | Statistics | |
|---|---|---|---|---|
| Age | 34.1 | 40.2 | 68.7 | F2,33 = 31.87 |
| (4.1) | (3.0) | (2.3) | p < 0.001 | |
| Gender | 6 Male | 5 Male | 7 Male | χ2 36 = 0.67 |
| 6 Female | 7 Female | 5 Female | p = 0.717 | |
| ESS | 5.0 | 16.9 | 7.3 | F2,33 = 30.23 |
| (1.0) | (1.4) | (1.2) | p < 0.001 | |
| BDI | 2.2 | 10.6 | 7.9 | F2,33 = 6.99 |
| (0.7) | (2.5) | (1.0) | p = 0.003 | |
| Medication | None (12) | None (4), Sodium Oxybate (5; of 1.5–4.5g))*, Modafinil (4; 100mg) | None (1), Levodopa (11; of 62.5-250mg), Clonazepam (3; of 0.25–0.5mg) + |
Participant demographics and statistical differences. ESS = Epworth Sleepiness Score, BDI = Beck’s Depression Inventory, ULN = Ullanlinna Narcolepsy Scale.
*1 NC patient took both Sodium Oxybate and Modafinil.
+3 Parkinson’s patients took a combination of Levodopa and Clonazepam.